These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6407548)

  • 1. Enhanced iron removal from liver parenchymal cells in experimental iron overload: liposome encapsulation of HBED and phenobarbital administration.
    Rahman YE; Cerny EA; Lau EH; Carnes BA
    Blood; 1983 Jul; 62(1):209-13. PubMed ID: 6407548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of iron removal from the reticuloendothelial system by liposome encapsulation of N,N'-bis[2-hydroxybenzyl]-ethylenediamine-N,N'-diacetic acid (HBED). Comparison with desferrioxamine.
    Lau EH; Cerny EA; Wright BJ; Rahman YE
    J Lab Clin Med; 1983 May; 101(5):806-16. PubMed ID: 6403640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposome-encapsulated desferrioxamine in experimental iron overload.
    Lau EH; Cerny EA; Rahman YE
    Br J Haematol; 1981 Apr; 47(4):505-18. PubMed ID: 7213574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HBED: the continuing development of a potential alternative to deferoxamine for iron-chelating therapy.
    Bergeron RJ; Wiegand J; Brittenham GM
    Blood; 1999 Jan; 93(1):370-5. PubMed ID: 9864183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HBED: A potential alternative to deferoxamine for iron-chelating therapy.
    Bergeron RJ; Wiegand J; Brittenham GM
    Blood; 1998 Feb; 91(4):1446-52. PubMed ID: 9454776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel double prodrugs of the iron chelator N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED): Synthesis, characterization, and investigation of activation by chemical hydrolysis and oxidation.
    Thiele NA; Abboud KA; Sloan KB
    Eur J Med Chem; 2016 Aug; 118():193-207. PubMed ID: 27128183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and evaluation of the improved iron chelating agents EHPG, HBED and their dimethyl esters.
    Hershko C; Grady RW; Link G
    Haematologia (Budap); 1984; 17(1):25-33. PubMed ID: 6427069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Double Prodrug with Improved Membrane Permeability over the Parent Chelator HBED Provides Superior Cytoprotection against Hydrogen Peroxide.
    Thiele NA; Sloan KB
    ChemMedChem; 2016 Aug; 11(15):1596-9. PubMed ID: 27440560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenolic ethylenediamine derivatives: a study of orally effective iron chelators.
    Hershko C; Grady RW; Link G
    J Lab Clin Med; 1984 Mar; 103(3):337-46. PubMed ID: 6699459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of a novel iron chelator (HBED; (N,N'-Di(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid)) in equine (Equus caballus) as a model for black rhinoceros (Diceros bicornis).
    Sullivan KE; Lavin SR; Livingston S; Knutson M; Valdes EV; Warren LK
    J Anim Physiol Anim Nutr (Berl); 2022 Sep; 106(5):1107-1117. PubMed ID: 35894091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning.
    Bergeron RJ; Wiegand J; Brittenham GM
    Blood; 2002 Apr; 99(8):3019-26. PubMed ID: 11929795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of oral iron chelators assayed in the rat.
    Kim BK; Huebers HA; Finch CA
    Am J Hematol; 1987 Mar; 24(3):277-84. PubMed ID: 3826055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifunctional antioxidant activity of HBED iron chelator.
    Samuni AM; Afeworki M; Stein W; Yordanov AT; DeGraff W; Krishna MC; Mitchell JB; Brechbiel MW
    Free Radic Biol Med; 2001 Jan; 30(2):170-7. PubMed ID: 11163534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of fecal and urinary iron excretion in desferrioxamine-treated rats.
    Hershko C
    Blood; 1978 Mar; 51(3):415-23. PubMed ID: 623907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposome entrapped desferrioxamine and iron transporting ionophores: a new approach to iron chelation therapy.
    Young SP; Baker E; Huehns ER
    Br J Haematol; 1979 Mar; 41(3):357-63. PubMed ID: 427040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Fe-HBED and Fe-EHPG as hepatobiliary MR contrast agents.
    Hoener B; Engelstad BL; Ramos EC; Macapinlac HA; Price DC; Johnson TR; White DL
    J Magn Reson Imaging; 1991; 1(3):357-62. PubMed ID: 1802149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimalarial effect of HBED and other phenolic and catecholic iron chelators.
    Yinnon AM; Theanacho EN; Grady RW; Spira DT; Hershko C
    Blood; 1989 Nov; 74(6):2166-71. PubMed ID: 2508794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of iron chelation by desferrioxamine entrapped in red blood cell ghosts.
    Green R; Miller J; Crosby W
    Blood; 1981 May; 57(5):866-72. PubMed ID: 7214016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
    Kontoghiorghes GJ; Sheppard L; Hoffbrand AV; Charalambous J; Tikerpae J; Pippard MJ
    J Clin Pathol; 1987 Apr; 40(4):404-8. PubMed ID: 3584483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocyte iron kinetics in the rat explored with an iron chelator.
    Pippard MJ; Johnson DK; Finch CA
    Br J Haematol; 1982 Oct; 52(2):211-24. PubMed ID: 7126464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.